Articles

December 7, 2020 Alnylam Publishes Its 1st-Ever Rare Disease Trend Report Alnylam's 2020 Rare Disease Trend Report features findings from interviews with 30 U.S. payer and plan decision-makers about barriers to orphan drug access. Read More ›
December 7, 2020 Alnylam Releases 2nd Annual Patient Access Philosophy Report The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics. Read More ›
November 20, 2020 6 in a Row! Alnylam Named a Boston Globe Top Place to Work for 2020 Alnylam has been named to The Boston Globe's Top Places to Work list for 2020, marking 6th years in a row. Read More ›
November 5, 2020 My Journey to an AHP Diagnosis: Claire and Candace Claire and Candace share their stories of their long journeys to an acute hepatic porphyria (AHP) diagnosis. Read More ›
October 29, 2020 Alnylam Named a Science Magazine Top Employer for 2nd Year in a Row Alnylam has been named to Science Magazine and Science Career's Top Employers list for the second year in a row. Read More ›
October 1, 2020 A New European Biotech Social Pact The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and... Read More ›
September 14, 2020 Navigating AHP and Pain During a Pandemic As the COVID-19 pandemic continues to have a significant impact on people and communities around the world, it poses unique challenges for people living with AH Read More ›
September 2, 2020 With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ... What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which Europ Read More ›
August 6, 2020 Alnylam Promotes Dr. Yvonne Greenstreet to President & COO Dr. Yvonne Greenstreet, has been elevated to the role of President of Alnylam. She will retain her COO role as well. Read More ›
August 3, 2020 How to Evaluate a Medicine for the Treatment of an Ultra-rare Disease Such as PH1 For a new medicine to become available, it needs to undergo stringent testing in clinical trials to evaluate its safety and, importantly, its efficacy (how well Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site